- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02289157
Negative Pressure Wound Therapy in Cesarean Section (NPWTCS)
Negative Pressure Wound Therapy in High Risk Patients Undergoing Cesarean
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This will be a prospective, randomized, controlled trial of pregnant women who present for prenatal care at Parkland Health and Hospital System. The participants will be limited to women undergoing a cesarean section who are high risk for wound complications: all patients with a BMI > 40 undergoing cesarean section.
The primary outcome will be wound complication defined as wound disruption or wound infection. A wound disruption will be defined as the partial or complete opening of the deep subcutaneous space, not to include superficial skin separation. Underlying causes will include seroma, hematoma, abscess, and facial dehiscence. Wound infection will be defined as a physician diagnosis of wound infection with erythema and warmth extending beyond the immediate area adjacent to the incision and requiring treatment with antibiotics.
All patients with a BMI > 40 undergoing scheduled cesarean section and patients with a BMI >40 who are admitted in labor will be approached to participate in the study. If patients meeting this criteria undergo cesarean section, they will be randomized to negative pressure wound therapy or a standard dressing. All labor treatment, pre-operative antibiotics, surgical technique, and post-operative care will not differ from current standard of care. All patients randomized will be included in the study.
All study participants will have the thickness of their subcutaneous tissue measured with a sterile ruler. Patients randomized to NPWT will have a negative pressure wound therapy system placed over her incision per the manufacturer's protocol. All patients randomized to standard dressing will have the customary dressing of gauze and surgical tape placed over her incision.
The investigators will be utilizing a single use negative pressure wound therapy system for the study. Single use negative pressure wound therapy systems are composed of a pressure pump and dressing kit. The pump creates a negative pressure of 125 mmHg (+/- 20 mgHg) and the dressing directly covers surgical incision. The system is battery-powered and designed to be used for a minimum of two days and a maximum of seven days of continuous use.
All randomized patients will undergo an examination of their incision by a research physician or nurse prior to discharge. The NPWT will be removed prior to discharge or on post-operative day seven, whichever comes first. All postpartum patients who undergo a cesarean delivery are inpatients until at least post-operative day three and will continue use of NPWT until day of discharge. In patients randomized to a standard dressing, the dressing will be removed prior to discharge per current standard of care.
All randomized patients will also undergo a 2 week post-operative incisional examination by a research physician or nurse at the obstetrical complications clinic. Patients will be followed until 30 days postpartum for any wound complications to include wound infection (superficial and deep), readmission to the hospital, re-operation for wound complications, hematoma, seroma, dehiscence, superficial infection requiring antibiotics, or additional clinical evaluations for wound care in the emergency room or clinic setting. A research physician or nurse will contact each after at least 30 days post-operative to confirm the patients' status and ensure no evaluations, admissions, or interventions were done at outside facilities.
Subjects will exit the study if they are unable to complete the post-operative visit or withdrawal consent for participation.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75235
- Parkland Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pregnant women with BMI > 40 undergoing a cesarean delivery at Parkland Health and Hospital System.
Exclusion Criteria:
- Any patient not meeting inclusion criteria will be deemed ineligible.
- All HIV positive patients will be excluded due to the increased risk of infectious complications in these patients.
- Although patients on anticoagulants can use NPWT, they will be excluded as there may be an increased risk of bleeding in these patients.
according to the wound therapy manufacturer's instructions patients with:
- fragile skin
- allergy to silver or acrylic adhesives
- a malignancy in the wound bed or margins of the wound bed
- non-enteric and unexplored fistulas
- necrotic tissue with eschar present
- exposed arteries, veins, nerves or organs, anastomotic sites, or surgical suction are not candidates for usage of the device.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Negative Pressure Wound Therapy
After standard cesarean section completed patients will have Prevena negative pressure wound therapy system placed.
|
Single use negative pressure wound therapy systems are composed of a pressure pump and dressing kit.
The pump creates a negative pressure of 125 mmHg (+/- 20 mgHg) and the dressing directly covers surgical incision.
The system is battery-powered and designed to be used for a minimum of two days and a maximum of seven days of continuous use.
The investigators hypothesize that negative pressure wound therapy will decrease the wound complications in these patients.
The investigators will be using Prevena Incision Management System as the negative pressure device in our study.
Other Names:
|
|
No Intervention: Standard dressing
After standard cesarean section completed patients will have standard dressing placed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Wound Complication
Time Frame: Day of surgery to 30 days postoperative
|
Number of Patients with Wound infection complications: hematoma, seroma, dehiscence, or Surgical Site Infection.
|
Day of surgery to 30 days postoperative
|
|
Number of Participants With Classification of Wound Morbidity
Time Frame: Day of Surgery to 30 days postoperative
|
Listing of different types of wound morbidity in the 2 cohorts: dehiscence, cellulitis, superficial SSI, deep SSI, organ space SSI
|
Day of Surgery to 30 days postoperative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Length of Postoperative Stay
Time Frame: Length of Postoperative Stay
|
Number of Days in Hospital after Initial Surgery
|
Length of Postoperative Stay
|
|
Length of Stay After Readmission
Time Frame: After dismissal and readmitted within 30 days for wound morbidity
|
Number of days in hospital after readmission for wound morbidity
|
After dismissal and readmitted within 30 days for wound morbidity
|
|
Number of Patients With Emergency Room Visits After Discharge
Time Frame: Day of surgery to 30 days postoperative
|
Number of emergency room visits made after initial discharge by the study (icNPT) and comparison groups.
|
Day of surgery to 30 days postoperative
|
|
Number of Patients With Number of Clinic Visits
Time Frame: Day of surgery to 30 days postoperative
|
Number of clinic visits made by patients after surgery concerning wound morbidity per patient
|
Day of surgery to 30 days postoperative
|
|
Number of Participants With Morbid Outcomes After Delivery
Time Frame: Day of Surgery to 30 days postoperative
|
Day of Surgery to 30 days postoperative
|
|
|
Number of Participants With Scheduled and Unscheduled Cesarean Section
Time Frame: Day of Surgery to 30 days postoperative
|
Cochran Mantel-Hanzel measures used to compare interactions between scheduled and unscheduled cesarean sections stratified by icNPT and standard dressing, for wound morbidity
|
Day of Surgery to 30 days postoperative
|
|
Number of Participants With Pfannenstiel Versus Midline Abdominal Incisions for Cesarian Section
Time Frame: Day of Surgery to 30 days postoperative
|
Cochran-Mantel-Haenzel test for interactions between pfannenstiel and midline abdominal incisions stratified by icNPT vs Standard dressing, for wound morbidity
|
Day of Surgery to 30 days postoperative
|
|
Number of Patients With Ruptured and Unruptured Membranes Prior to Cesarean Section
Time Frame: Day of Surgery to 30 days postoperative
|
Cochran-Mantel-Haenzel measure used to compare interaction in icNPT and Standard dressing stratified by Ruptured vs Unruptured membranes
|
Day of Surgery to 30 days postoperative
|
|
Number of Patients in Labor Versus no Labor Prior to Cesarean Section
Time Frame: Day of Surgery to 30 days postoperative
|
Cochran-Mantel-Haenzel measure used to compare interaction in icNPT and Standard dressing stratified by patients in labor and patients not in labor
|
Day of Surgery to 30 days postoperative
|
|
Number of Patients With Hypertension Versus no Hypertension
Time Frame: Day of Surgery to 30 days postoperative
|
Cochran-Mantel-Haenzel measure used to compare interaction between patients with hypertension versus no hypertension stratified by icNPT versus standard dressing, in wound morbidity
|
Day of Surgery to 30 days postoperative
|
|
Number of Patients With Insulin Requiring Diabetes Versus no Insulin Requiring Diabetes
Time Frame: Day of Surgery to 30 days postoperative
|
Cochran-Mantel-Haenzel measure used to compare interaction in icNPT and Standard wound dressings stratified by women with insulin requiring diabetes and no insulin requiring Diabetes.
|
Day of Surgery to 30 days postoperative
|
|
Number of Patients With Chorioamnionitis Versus no Chorioamnionitis
Time Frame: Day of Surgery to 30 days postoperative
|
Cochran-Mantel-Haenzel measure used to estimate interaction between chorioamnionitis and no chorioamnionitis stratified by icNPT and standard dressing, for wound morbidity
|
Day of Surgery to 30 days postoperative
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Scott Roberts, MD, UT southwestern Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STU 042014-047
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postoperative Wound Complications
-
Carilion ClinicSmith & Nephew, Inc.; DeRoyal Industries, Inc.CompletedImpaired Wound Healing | Postoperative Wound Infection-deepUnited States
-
PolyPid Ltd.CompletedPostoperative Wound Infection Superficial Incisional | Postoperative Wound Infection Deep Incisional Surgical SiteIsrael
-
Pulmatrix Inc.TerminatedPost Operative Wound Infection | Postoperative Wound Infection-deepUnited States
-
Children's Healthcare of AtlantaWithdrawnPostoperative Wound InfectionUnited States
-
Military Medical AcademyRecruitingPostoperative Wound Infection Superficial Incisional | Postoperative Wound Infection Deep Incisional Surgical SiteBulgaria
-
Charite University, Berlin, GermanyUnknownPostoperative Wound Infection | Postoperative OutcomeGermany
-
Michał PędziwiatrCompletedSurgical Wound | Negative Pressure Wound Therapy | Stoma Ileostomy | Postoperative Wound InfectionPoland
-
Cairo UniversityRecruitingPostoperative Infection | Cesarean Section Complications | Vaginal InfectionEgypt
-
Universitat Internacional de CatalunyaHospital de GranollersCompletedSurgical Wound Infection | Postoperative Wound Infection | Postoperative Wound Infection Superficial Incisional | Preventive TherapySpain
-
Mashhad University of Medical SciencesUnknown
Clinical Trials on Negative pressure wound therapy
-
ConvaTec Inc.WithdrawnSurgical Wound, Recent | Trauma-related Wound | Dehiscence Wound | Surgical Wound LeakUnited States
-
Sindh Institute of Urology and TransplantationCompletedSurgical Site Infection | Wound Heal | Negative-Pressure Wound Therapy | Stoma Site InfectionPakistan
-
Henry Ford Health SystemWithdrawnSurgical Site Infection | Groin InfectionsUnited States
-
Region SkaneRecruitingPostoperative Complications | Surgical Wound Infection | Skin Cancer | Wound Healing | Bandages | Negative-Pressure Wound Therapy | Skin Grafting | Lower Extremity | Skin Transplantation | Split Thickness Skin Graft | Skin Tumour | LegSweden
-
H. Lee Moffitt Cancer Center and Research InstituteActive, not recruitingSurgical Wound InfectionUnited States
-
Murk NiazCompletedSurgical Site Infection | Hepatobiliary Disease | Hepatobiliary DisordersPakistan
-
Zuyderland Medisch CentrumCompletedBreast Cancer | Wound Infection | Wound Complication | Wound Dehiscence | Wound NecrosisNetherlands
-
Royal College of Surgeons, IrelandRecruitingWound Healing | Pilonidal SinusIreland
-
Zuyderland Medisch CentrumRecruitingBreast Cancer | Seroma | Wound ComplicationNetherlands